WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Prostate Cancer Efficacy Endpoints_v2, New Lesions ???? Anatomical location, Patient Reported Outcomes defined as Pain, Patient Reported Outcomes defined as Fatigue, Existing lesion identified by Anatomical region, Therapeutic Efficacy Endpoint is intersection of Therapeutic Intervention, Time-To-Event end points include Time to First Skeletal-related Event, Bone Disease identified by New Lesions, New lesion identified by Organ specific lesion ID, Time to PSA Progression measured with PSA, - CR - PR differentiated into Unconfirmed Response, LD (axial plane) for target lesion measured in mm, Sum of longest diameters (SLD) have response options -Complete Response (CR) -Partial Response (PR) -Not all evaluated -Stable disease (SD) -Progressive disease (PD) -Any, Time to opiate use derived from Pain Assessment Tool, Therapeutic Efficacy Endpoint is intersection of Observation or Assessment, Overall Survival (OS) derived from Circulating Tumor Cells (CTC), Anatomical region instantiated by -Lung -CNS (brain, leptomeninges) -Bone -Liver -Adrenal (L, R) -Mediastinum (anterior, middle, posterior) -Hilar (L, R) -Plural Fluid, Time to Pain Progression derived from Pain Assessment Tool, Sum of longest diameters (SLD) has component LD (axial plane) for target lesion, Target lesion evaluated by Quantitative assessment, Overall Survival (OS) measured by Date of Randomization